NCT00048945View on ClinicalTrials.gov

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

PHASE3CompletedINTERVENTIONAL
Enrollment

820

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Chronic Hepatitis B
Interventions
DRUG

PEGASYS

Trial Locations (74)

100

Taipei

114

Taipei

2139

Concord

4029

Herston

4031

Basel

10330

Bangkok

10400

Bangkok

10700

Bangkok

13353

Berlin

30308

Atlanta

30623

Hanover

31096

Haifa

40225

Düsseldorf

44791

Bochum

48109

Ann Arbor

49100

Petah Tikva

50202

Chiang Mai

50931

Cologne

64239

Tel Aviv

68501

Lincoln

69288

Lyon

78612

Cedar Creek

81377

München

84121

Salt Lake City

85259

Scottsdale

90048

Los Angeles

90112

Songkhla

90242

Downey

91105

Pasadena

92110

Clichy

94115

San Francisco

96817

Honolulu

98195

Seattle

100011

Beijing

100034

Beijing

100039

Beijing

100050

Beijing

100054

Beijing

159402

Singapore

169608

Singapore

200025

Shanghai

200040

Shanghai

200433

Shanghai

228510

Singapore

310003

Hangzhou

400010

Chongqing

510515

Guangzhou

510630

Guangzhou

610041

Chengdu

02111

Boston

55404-4565

Minneapolis

27599-7080

Chapel Hill

13081-970

Campinas

90035-003

Porto Alegre

40150-130

Salvador

01246-900

São Paulo

T2N 4N1

Calgary

M5G 1L7

Toronto

M5G 1X5

Toronto

Unknown

Hong Kong

Otahuhu

Kaohsiung City

Kwei Shan

Tainan City

Taipei

15-540

Bialystok

85-030

Bydgoszcz

01-201

Warsaw

00909

Santurce

120-752

Seoul

135-170

Seoul

138-736

Seoul

150-713

Seoul

NG2 3HF

Nottingham

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00048945 - Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B | Biotech Hunter | Biotech Hunter